Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Snowdon, C. Kernaghan, S. Moretti, L. Turner, N.C. Ring, A. Wilkinson, K. Martin, S. Foster, S. Kilburn, L.S. Bliss, J.M. (2022). Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Trials, Vol.23 (1), pp. 372-?.  show abstract

Bachelot, T. Cottu, P. Chabaud, S. Dalenc, F. Allouache, D. Delaloge, S. Jacquin, J.-. Grenier, J. Venat Bouvet, L. Jegannathen, A. Campone, M. Del Piano, F. Debled, M. Hardy-Bessard, A.-. Giacchetti, S. Mouret-Reynier, M.-. Barthelemy, P. Kaluzinski, L. Mailliez, A. Legouffe, E. Sephton, M. Bliss, J. Canon, J.-. Penault-Llorca, F. Lemonnier, J. Cameron, D. Andre, F. (2022). Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. , Vol.40 (32), pp. 3699-3708.  show abstract

Tolaney, S.M. Garrett-Mayer, E. White, J. Blinder, V.S. Foster, J.C. Amiri-Kordestani, L. Hwang, E.S. Bliss, J.M. Rakovitch, E. Perlmutter, J. Spears, P.A. Frank, E. Tung, N.M. Elias, A.D. Cameron, D. Denduluri, N. Best, A.F. DiLeo, A. Baizer, L. Butler, L.P. Schwartz, E. Winer, E.P. Korde, L.A. (2021). Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2 0. Journal of clinical oncology : official journal of the american society of clinical oncology, , pp. JCO2003613-?.  show abstract

Kingston, B. Cutts, R.J. Bye, H. Beaney, M. Walsh-Crestani, G. Hrebien, S. Swift, C. Kilburn, L.S. Kernaghan, S. Moretti, L. Wilkinson, K. Wardley, A.M. Macpherson, I.R. Baird, R.D. Roylance, R. Reis-Filho, J.S. Hubank, M. Faull, I. Banks, K.C. Lanman, R.B. Garcia-Murillas, I. Bliss, J.M. Ring, A. Turner, N.C. (2021). Genomic profile of advanced breast cancer in circulating tumour DNA. Nature communications, Vol.12 (1), pp. 2423-?.  show abstract

Murray Brunt, A. Haviland, J.S. Wheatley, D.A. Sydenham, M.A. Alhasso, A. Bloomfield, D.J. Chan, C. Churn, M. Cleator, S. Coles, C.E. Goodman, A. Harnett, A. Hopwood, P. Kirby, A.M. Kirwan, C.C. Morris, C. Nabi, Z. Sawyer, E. Somaiah, N. Stones, L. Syndikus, I. Bliss, J.M. Yarnold, J.R. FAST-Forward Trial Management Group, (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet (london, england), Vol.395 (10237), pp. 1613-1626.  show abstract

Brunt, A.M. Haviland, J.S. Sydenham, M. Agrawal, R.K. Algurafi, H. Alhasso, A. Barrett-Lee, P. Bliss, P. Bloomfield, D. Bowen, J. Donovan, E. Goodman, A. Harnett, A. Hogg, M. Kumar, S. Passant, H. Quigley, M. Sherwin, L. Stewart, A. Syndikus, I. Tremlett, J. Tsang, Y. Venables, K. Wheatley, D. Bliss, J.M. Yarnold, J.R. (2020). Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.38 (28), pp. 3261-3272.  show abstract

Turner, N.C. Kingston, B. Kilburn, L.S. Kernaghan, S. Wardley, A.M. Macpherson, I.R. Baird, R.D. Roylance, R. Stephens, P. Oikonomidou, O. Braybrooke, J.P. Tuthill, M. Abraham, J. Winter, M.C. Bye, H. Hubank, M. Gevensleben, H. Cutts, R. Snowdon, C. Rea, D. Cameron, D. Shaaban, A. Randle, K. Martin, S. Wilkinson, K. Moretti, L. Bliss, J.M. Ring, A. (2020). Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. The lancet. oncology, Vol.21 (10), pp. 1296-1308.  show abstract

Smith, I. Robertson, J. Kilburn, L. Wilcox, M. Evans, A. Holcombe, C. Horgan, K. Kirwan, C. Mallon, E. Sibbering, M. Skene, A. Vidya, R. Cheang, M. Banerji, J. Morden, J. Sidhu, K. Dodson, A. Bliss, J.M. Dowsett, M. (2020). Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. The lancet. oncology, Vol.21 (11), pp. 1443-1454.  show abstract

Piccart, M.J. Hilbers, F.S. Bliss, J.M. Caballero, C. Frank, E.S. Renault, P. Naït Kaoudjt, R. Schumacher, E. Spears, P.A. Regan, M.M. Gelber, R.D. Davidson, N.E. Norton, L. Winer, E.P. BIG-NABCG Collaboration, (2020). Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.38 (34), pp. 4120-4129.  show abstract

Bhattacharya, I.S. Haviland, J.S. Kirby, A.M. Kirwan, C.C. Hopwood, P. Yarnold, J.R. Bliss, J.M. Coles, C.E. IMPORT Trialists, (2019). Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial. Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.37 (4), pp. 305-317.  show abstract

Judson, I. Morden, J.P. Kilburn, L. Leahy, M. Benson, C. Bhadri, V. Campbell-Hewson, Q. Cubedo, R. Dangoor, A. Fox, L. Hennig, I. Jarman, K. Joubert, W. Kernaghan, S. López Pousa, A. McNeil, C. Seddon, B. Snowdon, C. Tattersall, M. Toms, C. Martinez Trufero, J. Bliss, J.M. (2019). Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. The lancet. oncology, Vol.20 (7), pp. 1023-1034.  show abstract

O'Leary, B. Hrebien, S. Morden, J.P. Beaney, M. Fribbens, C. Huang, X. Liu, Y. Bartlett, C.H. Koehler, M. Cristofanilli, M. Garcia-Murillas, I. Bliss, J.M. Turner, N.C. (2018). Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nature communications, Vol.9 (1), pp. 896-?.  show abstract

Tutt, A. Tovey, H. Cheang, M.C. Kernaghan, S. Kilburn, L. Gazinska, P. Owen, J. Abraham, J. Barrett, S. Barrett-Lee, P. Brown, R. Chan, S. Dowsett, M. Flanagan, J.M. Fox, L. Grigoriadis, A. Gutin, A. Harper-Wynne, C. Hatton, M.Q. Hoadley, K.A. Parikh, J. Parker, P. Perou, C.M. Roylance, R. Shah, V. Shaw, A. Smith, I.E. Timms, K.M. Wardley, A.M. Wilson, G. Gillett, C. Lanchbury, J.S. Ashworth, A. Rahman, N. Harries, M. Ellis, P. Pinder, S.E. Bliss, J.M. (2018). Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature medicine, Vol.24 (5), pp. 628-637.  show abstract

Coles, C.E. Griffin, C.L. Kirby, A.M. Titley, J. Agrawal, R.K. Alhasso, A. Bhattacharya, I.S. Brunt, A.M. Ciurlionis, L. Chan, C. Donovan, E.M. Emson, M.A. Harnett, A.N. Haviland, J.S. Hopwood, P. Jefford, M.L. Kaggwa, R. Sawyer, E.J. Syndikus, I. Tsang, Y.M. Wheatley, D.A. Wilcox, M. Yarnold, J.R. Bliss, J.M. IMPORT Trialists, (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet (london, england), Vol.390 (10099), pp. 1048-1060.  show abstract

Ellis, P. Barrett-Lee, P. Johnson, L. Cameron, D. Wardley, A. O'Reilly, S. Verrill, M. Smith, I. Yarnold, J. Coleman, R. Earl, H. Canney, P. Twelves, C. Poole, C. Bloomfield, D. Hopwood, P. Johnston, S. Dowsett, M. Bartlett, J.M. Ellis, I. Peckitt, C. Hall, E. Bliss, J.M. TACT Trial Management Group, TACT Trialists, (2009). Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet, Vol.373 (9676), pp. 1681-1692.  show abstract

START Trialists' Group, Bentzen, S.M. Agrawal, R.K. Aird, E.G. Barrett, J.M. Barrett-Lee, P.J. Bliss, J.M. Brown, J. Dewar, J.A. Dobbs, H.J. Haviland, J.S. Hoskin, P.J. Hopwood, P. Lawton, P.A. Magee, B.J. Mills, J. Morgan, D.A. Owen, J.R. Simmons, S. Sumo, G. Sydenham, M.A. Venables, K. Yarnold, J.R. (2008). The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet oncol, Vol.9 (4), pp. 331-341.  show abstract

START Trialists' Group, Bentzen, S.M. Agrawal, R.K. Aird, E.G. Barrett, J.M. Barrett-Lee, P.J. Bentzen, S.M. Bliss, J.M. Brown, J. Dewar, J.A. Dobbs, H.J. Haviland, J.S. Hoskin, P.J. Hopwood, P. Lawton, P.A. Magee, B.J. Mills, J. Morgan, D.A. Owen, J.R. Simmons, S. Sumo, G. Sydenham, M.A. Venables, K. Yarnold, J.R. (2008). The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet, Vol.371 (9618), pp. 1098-1107.  show abstract

Coleman, R.E. Banks, L.M. Girgis, S.I. Kilburn, L.S. Vrdoljak, E. Fox, J. Cawthorn, S.J. Patel, A. Snowdon, C.F. Hall, E. Bliss, J.M. Coombes, R.C. (2007). Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet oncology, Vol.8 (2), pp. 119-9.

Adjuvant Breast Cancer Trialists Collaborative Group, Collaborator: J Bliss, (2007). Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. J natl cancer inst, Vol.99 (7), pp. 506-515.

Johnston, S. Puhalla, S. Wheatley, D. Ring, A. Barry, P. Holcombe, C. Boileau, J.F. Provencher, L. Robidoux, A. Rimawi, M. McIntosh, S.A. Shalaby, I. Stein, R.C. Thirlwell, M. Dolling, D. Morden, J. Snowdon, C. Perry, S. Cornman, C. Batten, L.M. Jeffs, L.K. Dodson, A. Martins, V. Modi, A. Osborne, C.K. Pogue-Geile, K.L. Cheang, M.C. Wolmark, N. Julian, T.B. Fisher, K. MacKenzie, M. Wilcox, M. Huang Bartlett, C. Koehler, M. Dowsett, M. Bliss, J.M. Jacobs, S.A. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial. Journal of clinical oncology, , pp. JCO.18.01624-JCO.18.01624.

Gnant, M. Dueck, A.C. Frantal, S. Martin, M. Burstein, H.J. Greil, R. Fox, P. Wolff, A.C. Chan, A. Winer, E.P. Pfeiler, G. Miller, K.D. Colleoni, M. Suga, J.M. Rubovsky, G. Bliss, J.M. Mayer, I.A. Singer, C.F. Nowecki, Z. Hahn, O. Thomson, J. Wolmark, N. Amillano, K. Rugo, H.S. Steger, G.G. Hernando Fernández de Aránguiz, B. Haddad, T.C. Perelló, A. Bellet, M. Fohler, H. Metzger Filho, O. Jallitsch-Halper, A. Solomon, K. Schurmans, C. Theall, K.P. Lu, D.R. Tenner, K. Fesl, C. DeMichele, A. Mayer, E.L. PALLAS groups and investigators, Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of clinical oncology : official journal of the american society of clinical oncology, Vol.40 (3), pp. 282-293.  show abstract

Coombes, R.C. Tovey, H. Kilburn, L. Mansi, J. Palmieri, C. Bartlett, J. Hicks, J. Makris, A. Evans, A. Loibl, S. Denkert, C. Murray, E. Grieve, R. Coleman, R. Borley, A. Schmidt, M. Rautenberg, B. Kunze, C.A. Rhein, U. Mehta, K. Mousa, K. Dibble, T. Lu, X.L. von Minckwitz, G. Bliss, J.M. Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators, Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. Jama oncology, Vol.7 (9), pp. 1291-1301.  show abstract